Evidence map›Paper›PMID 42271125›Full record

ArticleAnnals of surgical oncology2026

Long-Term Outcomes of Patients with Gastric Cancer and Positive Peritoneal Cytology.

Cary Jo R Schlick, Ryan J Ellis, Johan L Dikken, Sabrina T Lin, Marinela Capanu, Bhumika Jadeja, Murray F Brennan, Vivian E Strong, David H Ilson, Steven B Maron and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Cary Jo R Schlick *Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ryan J Ellis *Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Johan L DikkenDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sabrina T LinDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Marinela CapanuDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Bhumika JadejaDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Murray F BrennanDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Vivian E StrongDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
David H IlsonDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Steven B MaronDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yelena Y JanjigianDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Laura H TangDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Daniel G CoitDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. coitd@mskcc.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with gastric cancer and isolated positive peritoneal cytology have stage IV disease. The clinical significance of cytologic conversion is poorly understood. Our objectives are to (1) describe the clinicopathologic characteristics of patients with gastric cancer and isolated positive peritoneal cytology and their association with survival, (2) evaluate patients who underwent second cytologic evaluation for assessment of cytologic conversion, and (3) describe recurrence patterns in patients with cytologic conversion who underwent resection. PATIENTS AND

methodsPatients with gastric adenocarcinoma and isolated positive peritoneal cytology were identified from a prospectively maintained institutional database from 1996 to 2020 for this cohort study. Patients were characterized by selection for second cytologic evaluation following chemotherapy, cytologic conversion, and selection for surgical resection. Factors associated with overall survival (OS) were evaluated by time-dependent multivariable Cox regression models.

resultsOverall, 174 patients were identified, 62 (35.6%) were selected for second cytologic evaluation, 43 (69.4%) were cytologic converters, and 32 (74.4, 18.4% overall) underwent resection. Selection for second cytologic evaluation was associated with improved OS (hazard ratio [HR] 0.56, 95% CI 0.37-0.86), and among those patients, cytologic conversion was associated with improved OS (HR 0.17, 95% CI 0.08-0.35). Ten patients (31.3%) had no evidence of recurrence following resection during the study period. The peritoneum was the most common site of recurrence (n = 17, 53.1%).

conclusionsAmong patients with gastric cancer and isolated positive peritoneal cytology, second cytologic evaluation can provide prognostic information and inform treatment decisions. Cytologic conversion was documented in 25% of patients, with rare instances of long-term disease control.

Indexed as

AdenocarcinomaGastrectomyNeoplasm Recurrence, LocalPeritoneal NeoplasmsStomach NeoplasmsAgedCytodiagnosisFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisProspective StudiesRetrospective StudiesSurvival RateCytologic conversionGastrectomyGastric cancerIsolated positive peritoneal cytologyPeritoneal metastasesPositive peritoneal cytology

Identifiers

PMID42271125

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.